MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that its Oncodetect™ molecular residual disease (MRD) ...
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that ...
Exact Sciences Corporation (NASDAQ:EXAS) is one of the best mid cap pharma stocks to buy. On July 9, Exact Sciences announced that its Oncodetect molecular residual disease/MRD test received Medicare ...
Hosted on MSN
Exact Sciences (EXAS) Stock Trades Up, Here Is Why
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 2.2% in the afternoon session after the Nancy Gardner Sewell MCED Act advanced in the U.S. House, a development that could ...
Passage of MCED legislation marks major milestone for early cancer detection Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results